CB-103 is under clinical development by Cellestia Biotech and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CB-103’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 13 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CB-103 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CB-103 overview

CB-103 is under development for the treatment of notch dependent solid tumors including triple negative breast cancer, HER 2 positive and negative breast cancer, Estrogen-receptor positive (ER-positive) breast cancer, T-cell acute lymphoblastic leukemia (T-ALL), metastatic colorectal cancer, gastric cancer, metastatic ovarian cancer, cervical cancer, non-small cell lung cancer, metastatic melanoma, osteosarcoma, adenoid cystic carcinoma, glioblastoma multiforme, multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, follicular lymphoma, CNS lymphoma, diffuse large b-cell lymphoma, Burkitt lymphoma, marginal zone b-cell lymphoma, splenic marginal zone b-cell lymphoma, mantle cell lymphoma, anaplastic large cell lymphoma, peripheral t-cell lymphoma,desmoid tumors and central nervous system (CNS) lymphoma and for graft versus host disease.The drug candidate is administered through oral route and it is formulated as capsules. It acts by targeting the Notch intracellular domain.

It was under development for the treatment of rhabdomyosarcoma, fibrosarcoma, liposarcoma, cholangiocarcinoma.

Cellestia Biotech overview

Cellestia Biotech (Cellestia) is a biopharmaceutical company that develops anti-cancer drugs for the treatment of oncology and immunological disorders. The company’s lead compound includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. Its CB-103 blocks the notch pathway and inhibits cancerous cells in breast, lung, blood, or any other tissue of the body. Cellestia Biotech’s products finds application in the treatment of NOTCH dependent leukemia, lymphoma and solid tumors. The company conducts research and development activities in the field of oncology and cancer stem cells biology. It operates through its research laboratory located in Lausanne. Cellestia Biotech is headquartered in Basel, Switzerland.

Quick View CB-103 LOA Data

Report Segments
  • Innovator
Drug Name
  • CB-103
Administration Pathway
  • Oral
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
  • Sponsor Company: Cellestia Biotech
  • Originator: Ecole Polytechnique Federale de Lausanne
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.